Complete remission of unresectable colon cancer after preoperative chemotherapy selected by adenosine triphosphate-based chemotherapy response assay

Journal of Korean Medical Science

Volumn 23, Issue 5, 2008, Pages 916-919

  Jung, Wook Huh ^a   Yoon, Ah Park ^a   Eun, Joo Jung ^a   Kang, Young Lee ^a   Ji, Eun Kwon ^a   Sohn, Seung Kook ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Adenosine triphosphate; Colonic neoplasms; Complete remission; Drug screening assays, antitumor

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; OXALIPLATIN; PLATINUM COMPLEX;

ARTICLE; CASE REPORT; COLON TUMOR; HUMAN; LIVER TUMOR; MALE; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; REMISSION; TREATMENT OUTCOME;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 56049116740     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2008.23.5.916     Document Type: Article

References (12)

1. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghemard O, Levi F, Bismuth H. Rescue surgery for unresectable colorectal liver metastases down-staged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-57.
2. Cortazar P, Johnson BE. Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol 1999; 17: 1625-31.
3. Moon YW, Choi SH, Kim YT, Sohn JH, Chang J, Kim SK, Park MS, Chung KY, Lee HJ, Kim JH. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer. Cancer 2007; 109: 1829-35.
4. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schoffski P, Sobrero A, Van Cutsem E, Diaz-Rubio E. XELOX (capecitabine plus oxalipatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084-91.
5. Guillem JG, Puig-La Calle J Jr, Akhurst T, Tickoo S, Ruo L, Minsky BD, Gollub MJ, Kilmstra DS, Mazumdar M, Paty PB, Macapinlac H, Yeung H, Saltz L, Finn RD, Erdi Y, Humm J, Cohen AM, Larson S. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 2000; 43: 18-24.
6. Kaneki T, Koizumi T, Kawashima A, Tsushima K, Kubo K, Fujimoto K, Honda T, Akamatsu T. Double cancer (lung and colon cancer) that showed complete remission with irinotecan and cisplatin combined chemotherapy. J Gastroenterol 2000; 35: 864-9.
7. Brandi G, Pantaleo MA, Calabrese C, Di Battista M, Poggi R, Bajetta E, Biasco G. Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine. Int J Colorectal Dis 2004; 19: 599-602.
8. Huh JW, Park YA, Sohn SK, Choi SH. In-vitro chemosensitivity test for colorectal cancer using an adenosine-triphosphate-based chemotherapy response assay (ATP-CRA). J Korean Soc Coloproctol 2007; 23: 172-9.
9. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301-8.
10. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
11. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-37.
12. Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 2004; 22: 3631-8.